76 recruiting, 63 unknown, 32 completed, 21 not yet recruiting. 61 Phase 2, 53 Not applicable, 20 Phase 3, 17 Phase 1, 11 Phase 4.
Follow The First Affiliated Hospital of Xiamen University: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia venetoclax, chidamide, and chiglitazar sodium (VCC) - Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-11-11 | 2026-08-24 |
| Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients Protocolized HFNC Weaning Strategy, Usual Care HFNC Weaning - Acute Hypoxemic Respiratory Failure, High-Flow Nasal Cannula Therapy | Not applicable | Not yet recruiting | Rush University Medical Center | 2000 | 2026-11-01 | 2026-09-25 |
| 68Ga-XHER2 PET/CT for HER2 Assessment 68Ga-XHER2 PET/CT - Solid Tumor (Excluding CNS), HER2 | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 80 | 2026-10-22 | 2026-10-21 |
| 68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer 68Ga-XMFH01 PET/CT - Prostate Cancer (Diagnosis), ACP3 | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 25 | 2026-10-21 | 2026-10-21 |
| Anxiety and Depression in Patients With Hematologic Malignancies Baseline Anxiety and/or Depression - Hematologic Disease | Recruiting | The First Affiliated Hospital of Xiamen University | 100 | 2026-10-20 | 2026-10-20 | |
| A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer ICG-guided sentinel lymph node dissection, ICG-guided systematic lymph node dissection - Esophageal Cancer, Sentinel Lymph Node | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 200 | 2026-10-01 | 2026-08-26 |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
| Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer Compared the diagnostic performance of 68Ga-MY6349 PET/CT with 68Ga-FAPI PET/CT - Tumor, Solid Tumor | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 120 | 2026-08-01 | 2026-08-07 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| Development and Validation of a Colorectal Cancer Diagnostic Model Colorectal Cancer, Advanced Neoplasia | Not yet recruiting | Peking University Cancer Hospital & Institute | 20000 | 2026-07-15 | 2026-07-23 | |
| Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer Gastric Cancer (GC) | Active not recruiting | Nanfang Hospital, Southern Medical University | 80 | 2026-05-10 | 2026-06-03 | |
| DLL3-Targeted PET/CT in Small Cell Lung Cancer conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT - PET/CT, Small Cell Lung Cancer ( SCLC ) | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 20 | 2026-05-09 | 2026-07-01 |
| GPC3-Targeted PET/CT in Hepatocellular Carcinoma GPC3-targeted PET/CT - Hepatocellular Carcinoma (HCC), Glypican-3 | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 40 | 2026-05-01 | 2026-09-10 |
| rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) Recombinant Human Brain Natriuretic Peptide (rhBNP), Normal Saline (Placebo) - AKI - Acute Kidney Injury, Cardiac Surgical Procedures | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 694 | 2026-05-01 | 2026-06-01 |
| Multi-Site Cortical Puncture for DOR multiple ovarian cortex punctures, routine oocyte retrieval procedure - Diminished Ovarian Reserve (DOR) | Not applicable | Not yet recruiting | First Affiliated Hospital of Guangxi Medical University | 214 | 2026-04-30 | 2026-05-06 |
| GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL GB5005 CART - Non-hodgkin Lymphoma, Refractory Lymphoma | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 45 | 2026-04-30 | 2026-03-13 |
| Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease Tofacitinib - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 8 | 2026-04-24 | 2026-04-29 |
| A Phase II Study of NB001 for Acute Migraine Treatment One tablet of NB001 plus three tablets of placebo, Two tablets of NB001 plus two tablets of placebo, Four tablets of NB001 - Migraine | Phase 2 | Not yet recruiting | Chinese PLA General Hospital | 120 | 2026-04-20 | 2026-05-11 |
| Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome Thalidomide (50mg), Colchicine - Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome | Not applicable | Not yet recruiting | Wenjie Zheng | 106 | 2026-04-01 | 2026-03-17 |
Showing 20 of 206. Sign in to see all of them.
Disease (12) · Nasopharyngeal Carcinoma (10) · Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (8) · Leukemia, Myeloid, Acute (7) · Stomach Neoplasms (6) · Recurrence (5) · Dendritic Cell Sarcoma, Interdigitating (4) · Esophageal Neoplasms (4) · Esophageal Squamous Cell Carcinoma (4) · Lymphoma, Follicular (4) · Nasopharyngeal Neoplasms (4) · Obesity (4) · Overweight (4) · Prostatic Neoplasms (4)
Cisplatin (7) · apatinib (6) · Radiotherapy (5) · Rituximab (5) · Azacitidine (4) · Carboplatin (4) · Drug Therapy (4) · Paclitaxel (4) · Prednisone (4) · camrelizumab (4) · sintilimab (4) · Capecitabine (3) · Cyclophosphamide (3) · Docetaxel (3) · Granulocyte-Macrophage Colony-Stimulating Factor (3)
China (188) · Singapore (1) · Switzerland (1) · Taiwan (1) · United States (1)
Bing Xu (13) · Long Sun, PhD (9) · Baoping Xu, MD,PhD (3) · Haojun Chen, MD, PhD (3) · Kunling Shen, MD,PhD (3) · Baoping Xu, MD, PhD (2) · Bin Zheng (2) · Chunmei Bai, M.D. (2) · Fangsen Xiao, MD (2) · Feng Ye (2) · Guixiu Shi, PhD (2) · Jian-an Wang, MD, PhD (2) · Kunling Shen, MD, PhD (2) · Lijuan Yan (2) · Mingquan Cai (2)
PMID 10089184, PMID 10379732, PMID 11091234, PMID 11223832, PMID 11289756, PMID 11342888, PMID 11712875, PMID 11754382, PMID 1334988, PMID 14565873, PMID 15665225, PMID 15783049, PMID 16003309, PMID 16443041, PMID 16643334, PMID 17058319, PMID 17565630, PMID 18095269, PMID 18288753, PMID 18656040, PMID 18685899, PMID 18955183, PMID 19005182, PMID 19304694, PMID 19846234, PMID 20113944, PMID 20610241, PMID 20739054, PMID 20968209, PMID 21050026, PMID 21052986, PMID 21336514, PMID 21520200, PMID 21573742, PMID 21618575, PMID 21855968, PMID 22338149, PMID 22498635, PMID 22752074, PMID 23096171, PMID 23179732, PMID 24083332, PMID 24399492, PMID 24563870, PMID 24826062, PMID 24890883, PMID 25543701, PMID 25838180, PMID 26095785, PMID 26165587